Overview
Follistatin (FST) is a single-chain monomeric glycoprotein encoded by the FST gene. The 344 amino acid isoform (FST-344) is the predominant circulating form and the subject of most in vitro research due to its high-affinity binding of activin, myostatin (GDF-8), and related TGF-β superfamily members. First identified as a follicle-stimulating hormone-suppressing protein, FST-344 has since been characterised as a broad antagonist of multiple growth-regulating ligands with particular relevance to skeletal muscle biology.
Mechanism: High-Affinity Ligand Binding
Follistatin-344 neutralises its ligands by forming stable, non-signalling complexes that prevent receptor engagement. The crystal structure of the FST-activin A complex reveals that FST wraps around the ligand in an embrace-like configuration, burying the type I and type II receptor binding surfaces. Binding affinities (Kd) of FST-344 for myostatin and activin A fall in the picomolar to low nanomolar range in cell-free assays, making it one of the most potent endogenous antagonists of these pathways characterised.
Myostatin (GDF-8) is the primary negative regulator of skeletal muscle mass, signalling through ActRIIB and ALK4/5 receptors to activate SMAD2/3 phosphorylation and downstream inhibition of muscle protein synthesis. FST-344 prevents myostatin from engaging ActRIIB, effectively blocking the SMAD2/3 inhibitory cascade.
In Vitro Evidence: Skeletal Muscle Cells
In C2C12 myoblast cell culture systems, treatment with recombinant FST-344 at nanomolar concentrations consistently increases myotube diameter, myonuclei number, and markers of differentiation (MyoD, myogenin) compared to untreated controls. The effect is partially attributable to myostatin neutralisation and partially to activin A antagonism, as dual neutralisation produces additive increases in hypertrophic markers above either target alone.
Satellite cell (muscle stem cell) proliferation assays show enhanced BrdU incorporation and reduced apoptosis markers following FST-344 treatment, suggesting a role in supporting regenerative capacity beyond simple myostatin blockade.
Activin A and Systemic Wasting
Activin A contributes to skeletal muscle atrophy in cachexia and age-related sarcopenia models. FST-344’s ability to neutralise activin A in addition to myostatin positions it as a dual-target antagonist of catabolic signalling. Research in murine models of cancer-associated cachexia shows that FST-344 overexpression preserves lean mass at equivalent or greater levels than myostatin-specific antibodies alone, consistent with activin A playing a significant independent role in muscle wasting.
Considerations for In Vitro Research
FST-344 is a glycoprotein and requires careful handling to preserve tertiary structure and ligand-binding activity. Repeated freeze-thaw cycles, high-temperature storage, and extreme pH conditions can denature the protein and reduce binding affinity. Researchers should validate activity using cell-based myostatin neutralisation assays (e.g., SMAD2/3 phosphorylation inhibition in ActRIIB-expressing cells) when assessing lot-to-lot consistency.
Because FST-344 binds multiple TGF-β family members, interpretating results in complex cell culture systems requires appropriate controls to distinguish myostatin-specific from activin-mediated effects.
For research use only. Not for human consumption. All Stackpure peptides are supplied with a third-party COA confirming ≥99% purity by HPLC.